Experience

Syndax Pharmaceuticals

• United States
• Biotechnology Research
• 1 - 100 Employee

• President, Research & Development

  • Apr 2023 - Present

  NYC



AbbVie

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Head of Development and Chief Medical Officer

  • Feb 2020 - Apr 2023

• Head of Global Oncology Development

  • Nov 2017 - Feb 2020



Amgen

• United States
• Biotechnology Research
• 700 & Above Employee

• Head of Development, Oncology and Inflammation

  • May 2016 - Oct 2017

  Therapeutic Area Head, Oncology and Inflammation



Novartis Oncology

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Sr Vice President, Development; Global Program Head

  • Nov 2014 - May 2016

  NJ, USA



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Global Program Head

  • Jan 2012 - May 2016

  Basel Area, Switzerland



Novartis Oncology

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Oncology Clinical Development, Site Head, Basel

  • May 2010 - Jul 2012

• Senior Global Clinical Program Head

  • Aug 2010 - Dec 2011

  Global Program Head for CML and GIST Franchise, Novartis Oncology



Novartis Oncology

• Global Clinical Program Head

  • Oct 2006 - Apr 2010

  Basel, Switzerland Lead worldwide clinical development of Tasigna



Astex Therapeutics

• Head of Clinical Development

  • Jan 2005 - Aug 2006

  Established a clinical development department at Astex, a pre-IPO biotech company developing small molecule cancer therapeutics; oversaw the development of the company's first two clinical programs.



AstraZeneca

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Medical Director

  • Jul 2000 - Jan 2005

  Held several positions within oncology global clinical development with increasing responsibities. Developed several different cancer therapeutics including cytotoxic chemotherapy, tyrosine kinase inhibitors and hormonal therapies accross all phase of development from pre-clinical to phase IV. Although initially based in the UK I spent two years on international assignment in the US. gained broad regulatory experience in EU, USA and Japan.